Tag Archives: innovation

Call for Innovation Challenge Applicants

17 Jul

Life Science Nation invites all eligible early stage life science companies to apply to Innovation Challenge to showcase their technologies.

Companies from all categories of life science are encouraged to apply to Innovation Challenge for RESI Healthtech Week. Eligible companies can apply to Day 1, the First Coast Innovator’s Gathering, Day 2 RESI Global Partnering or both. Applicants will have the opportunity for excellent visibility among investors and strategic partners.

LSN is now accepting applications! The deadline is July 27, 2018.

For the first time this fall, Life Science Nation will have two days of Innovation Challenge competition as part of the RESI Healthtech Week (September 5-7, 2018). The Innovation Challenge offers selected companies the chance to gain more visibility from the early-stage investors in attendance.

Day 2 Redefining Early Stage Investments

All early-stage life science companies are eligible to apply. Finalists will be highlighted in multiple outlets:

  • Your country and technology highlighted at the conference
  • All conference attendees will have the chance to “invest” RESI Cash in their favorite technologies
  • LSN Newsletter Announcement to a readership of 20,000+
  • Featured on RESI Conference website Featured in the printed and online program guide
  • Winners will be announced during the cocktail reception
  • It is FREE to apply, click here.

Day 1, First Coast Innovation Challenge

All early-stage life science companies from DC through Boston are eligible to apply. Applicants will be highlighted in multiple outlets:

  • 10 finalists will be selected to pitch to a panel of investors
  • Applicants present a poster of their technology
  • All featured in the printed and online program guide
  • Attendees have access to partnering platform
  • Attendees have access to early-stage investor panels
  • Attendance on Day 1 for companies is $300, click here.

9 Hamilton Place, Suite 2B, Boston, MA 02108 +1 617-600-0668 | resi@lifesciencenation.com

New CFDA Regulations Already Showing Benefits for China’s Biotech Innovation

1 Mar

By James Huang, Research Analyst, LSN

james-wpWithin the last few months, China has been formally rolling out their new CFDA regulations that have given startups and new technology developers in China all sorts of benefits. These benefits include allowing the submission of data from clinical trial sites outside of China, allowing more Chinese hospitals to run trials, and allowing drug makers who are waiting for the green light on a safety study to go ahead if they haven’t heard back from the CFDA within 60 days.

All these regulation changes have seen a big boom to China’s biotech innovations. In fact, many Taiwanese companies have seen this regulatory shift as an opportunity to get into the Chinese market. Companies such as Taiwan Liposome (TLC) have started joint ventures with Chinese investors in order to run trials and commercialize their products in China. With the ability to submit their clinical trial data from Taiwan and start their new trials more quickly in China, many of these companies expect to see NDA filings for their assets by the end of the year.

Another highlight of this new regulatory system is that CRISPR human trials have already started within Chinese hospitals. CRISPR in the US, on the other hand, has yet to receive any approval or the go ahead for such trials. Some describe this discrepancy as being the result of China’s lack of regulations. However, that is not necessarily the case. China’s new regulations are geared towards pushing new innovative technologies into trials and out onto market as quickly as possible and has the benefit of being a newly reformed system. In contrast, the US FDA is a much older system using regulations that have been built upon for years, resulting in a much slower and more meticulous process.

Therefore, it might be an advantageous for startups to consider working with Chinese investors through joint ventures. The benefits of having an accelerated clinical trial process with reduced trial costs may be worth the pain of forming a joint venture with a qualified Chinese partner. Of course, while the process of finding a qualified Chinese partner and working with them may be tedious on its own, it definitely should not be immediately discounted. Given how the times are changing, a global outlook towards potential partners and opportunities is becoming more and more necessary in order to succeed.

Digital Health: Two Panels Showcase the New Innovation Frontier at RESI X

25 Aug

By Lucy Parkinson, Director of Research, LSN

Boston is known for being the hub of the biotech world. But as software is eating the world, innovators are finding new avenues for digitization of healthcare. Some are tackling inefficiencies and bottlenecks in the healthcare delivery system; others are using big data algorithms to explore biological processes, make new discoveries, or find new signals in population health data.

RESI Boston will feature two panels that explore this collision between software and health. The Healthcare IT session will look at the current landscape in digital health investment. What kind of solutions are investors excited about, and how do they assess startups in this increasingly crowded sector?

Moderated by Michael A. Greeley, General Partner, Flare Capital Partners, the panelists are:

In Big Data in Healthcare, RESI will take a laser focused look at the new possibilities that data science is creating in biotech and health innovation. Five investors will explore what they’re looking for in a big data opportunity. The participants will be:

If you’d like to catch these panels in person, you can register for RESI now.


%d bloggers like this: